The Endo-PAT2000 adds an unparalleled dimension to the prevention of cardiovascular disease by enabling physicians to accurately measure endothelial function and modify patient management accordingly. The medical community has long sought a cost-effective and reliable method to detect endothelial dysfunction. Itamar Medical's Endo-PAT2000 meets this challenge, enhancing the traditional clinical settings’ diagnostic capabilities for endothelial dysfunction. The Endo-PAT2000 can be used in any setting, from hospital bedside to outpatient clinic.
"Itamar Medical is proud to bring our innovative PAT Technology to the medically-advanced Australian market," said Dov Rubin, President and CEO of Itamar Medical. "This is an important milestone for the Endo-PAT2000and for Itamar Medical's penetration into the Asia Pacific markets."
Lorrence Platania, Managing Director of JLM Accutek Healthcare, the authorized Endo-PAT2000 Australian distributor stated, "We are thrilled to partner with Itamar Medical to bring the Endo-PAT2000 to Australia. This certification paves the way for patients in Australia to get tested with the Endo-PAT2000, providing them with a comprehensive picture of their endothelial cell function, a critical factor in cardiac health."
Itamar Medical (TASE: ITMR) is a medical technology company developing noninvasive diagnostic systems using Peripheral Arterial Tone (PAT™) signal, including the Watch-PAT™ systems for the diagnosis of sleep related breathing disorders and the Endo-PAT™ systems for assessment of endothelial function, a condition recognized as an early stage of cardiovascular and cerebrovascular diseases. For further information see http://www.itamar-medical.com.
